11 月 25 日晚间，有机硅助剂龙头新亚强（证券代码： 603155 ）发布公告称，控股股东、 实际控制人之一 初 琳于 11 月 24 日与邯郸市城欣股权投资基金合伙企业（有限合伙）（以 下简称城欣基金）签署股份转让协议，约定初琳将其持有的 9442.03 万股股份 以 20.76 元 / 股的价格转让给城欣基金。 本次股份转让完成后，城欣基金将持有新亚强 29.90% 股份，成为新的控股股东，邯郸市国 资委将成为公司新任实际控制人。 【导读】新亚强拟易主邯郸市国资委，股价今日异动 中国基金报记者 夏天 值 得 注 意 的 是 ， 在 拟 易 主 公 告 发 布 前 ， 新 亚 强 股 价 已 提 前 " 抢 跑 " 。 1 1 月 2 5 日 ， 新 亚 强 股 价 高 开 高 走 ， 迅 速 封 涨 停 ， 最 新 市 值 报 5 6.9 0 亿 元 。 | | (V) | ע | | 603155 新亚强 | | | | 18.02 +1.64 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 10.01% ...

Core Viewpoint - On November 17, 2023, Boyuan Co., Ltd. experienced a decline of 3.80% in stock price, with a trading volume of 299 million yuan, indicating potential market concerns regarding the company's performance and investor sentiment [1]. Financing Summary - On the same day, Boyuan Co., Ltd. had a financing buy-in amount of 25.66 million yuan and a financing repayment of 35.66 million yuan, resulting in a net financing outflow of 9.99 million yuan [1]. - As of November 17, the total financing and securities lending balance for Boyuan Co., Ltd. was 169 million yuan, which represents 5.56% of its circulating market value [1]. - There were no shares sold or repaid in the securities lending segment on November 17, with a remaining balance of 0 yuan [1]. Company Overview - Boyuan Co., Ltd., established on August 6, 2008, is located in Shouguang City, Shandong Province, and specializes in the research, production, and sales of fine chemicals, including organic and inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The company's revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. - For the period from January to September 2025, Boyuan Co., Ltd. reported a revenue of 1.073 billion yuan, reflecting a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2]. Shareholder Information - As of November 10, 2025, Boyuan Co., Ltd. had 11,900 shareholders, a decrease of 12.88% from the previous period, with an average of 2,813 circulating shares per shareholder, an increase of 14.78% [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. - Notable new institutional shareholders include Zhonghang New Start Flexible Allocation Mixed A, holding 1.3456 million shares, and several other funds that have recently entered the shareholder list [3].

Core Viewpoint - The stock price of Boyuan Co., Ltd. has increased by 5.22% on November 14, reaching 93.30 CNY per share, with a total market capitalization of 12.469 billion CNY, indicating a continuous upward trend over the past three days with a cumulative increase of 5.45% [1] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008. The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane. It also engages in the recycling of iodine and precious metal materials [1] - The main revenue composition of Boyuan Co., Ltd. includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [1] Shareholder Information - Among the top ten circulating shareholders of Boyuan Co., Ltd., a fund under AVIC Fund ranks as a significant holder. The AVIC New Start Flexible Allocation Mixed A Fund (005537) entered the top ten shareholders in the third quarter, holding 1.3456 million shares, which accounts for 4.03% of the circulating shares. The estimated floating profit today is approximately 6.2304 million CNY [2] - During the three-day increase, the floating profit earned was 616.31 thousand CNY [2] Fund Manager Profile - The fund manager of AVIC New Start Flexible Allocation Mixed A Fund (005537) is Han Hao, who has been in the position for 7 years and 338 days. The total asset size of the fund is 15.589 billion CNY, with the best fund return during his tenure being 205.01% and the worst being -18.95% [3]

Core Insights - On November 12, Boyuan Co., Ltd. saw a stock increase of 1.35% with a trading volume of 211 million yuan [1] - The company reported a net financing purchase of 7.72 million yuan on the same day, with a total financing balance of 175 million yuan, accounting for 6.06% of its market capitalization [1][2] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with a planned listing date of December 11, 2024 [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Financial Performance - For the period from January to September 2025, Boyuan Co., Ltd. achieved a revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60% [2] - The net profit attributable to shareholders was 132 million yuan, showing a year-on-year decrease of 22.53% [2] Shareholder Information - As of November 10, 2025, the number of shareholders for Boyuan Co., Ltd. was 11,900, a decrease of 12.88% from the previous period [2] - The average circulating shares per person increased by 14.78% to 2,813 shares [2] - The company has distributed a total of 88.408 million yuan in dividends since its A-share listing [3] Institutional Holdings - As of September 30, 2025, several new institutional shareholders have entered, including: - China Aviation New Start Flexible Allocation Mixed A (005537) as the second-largest shareholder with 1.3456 million shares [3] - Hong Kong Central Clearing Limited as the third-largest shareholder with 964,400 shares [3] - Other new shareholders include Yongying New Materials and Penghua Huizhi [3]

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has experienced significant fluctuations, with a year-to-date increase of 151.82% but a recent decline of 3.42% over the last five trading days [1] Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Group 2: Financial Performance - For the period from January to September 2025, Boyuan achieved operating revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60% [2] - The net profit attributable to the parent company was 132 million yuan, showing a year-on-year decrease of 22.53% [2] - Cumulative cash dividends since the A-share listing amount to 88.408 million yuan [3] Group 3: Shareholder and Market Activity - As of October 20, 2025, the number of shareholders increased by 25.58% to 13,300, with an average of 2,502 circulating shares per person, a decrease of 20.37% [2] - The stock has appeared on the "Dragon and Tiger List" six times this year, with the most recent appearance on October 17, where it recorded a net buy of -20.2738 million yuan [1] - Major shareholders include various new institutional investors, with significant holdings from funds such as Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [3]

Core Insights - On October 24, Boyuan Co., Ltd. saw a stock price increase of 14.34% with a trading volume of 902 million yuan [1] - The company experienced a net financing outflow of 982.88 million yuan on the same day, with a total financing and securities balance of 1.92 billion yuan [1][2] Financing and Trading Data - On October 24, Boyuan Co., Ltd. had a financing purchase of 8970.56 million yuan, with a current financing balance of 1.92 billion yuan, representing 5.58% of the circulating market value [2] - There were no short sales or repayments on the same day, with a short balance of 0.00 yuan [2] Company Overview - Boyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with a listing date of December 11, 2024 [2] - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2] - The main revenue composition includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2] Shareholder and Financial Performance - As of October 20, the number of shareholders for Boyuan Co., Ltd. was 13,300, an increase of 25.58% from the previous period, with an average of 2502 circulating shares per person, a decrease of 20.37% [3] - For the period from January to September 2025, the company reported a revenue of 1.073 billion yuan, a year-on-year increase of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [3] Dividend and Institutional Holdings - Boyuan Co., Ltd. has distributed a total of 88.408 million yuan in dividends since its A-share listing [4] - As of September 30, 2025, several new institutional shareholders have emerged among the top ten circulating shareholders, including Zhonghang New Start Flexible Allocation Mixed A and Hong Kong Central Clearing Limited [4]

Group 1 - The stock of Baoyuan Co., Ltd. increased by 15.91% on October 16, with a trading volume of 1.016 billion yuan [1] - On the same day, Baoyuan Co. had a financing buy-in amount of 80.791 million yuan and a net financing buy-in of 17.657 million yuan, with a total financing and securities balance of 119 million yuan [1] - The current financing balance of Baoyuan Co. is 119 million yuan, accounting for 4.25% of its circulating market value [1] Group 2 - Baoyuan Co., Ltd. is located in Shouguang City, Shandong Province, and was established on August 6, 2008, with its main business involving the research, production, and sales of fine chemicals [2] - The company's main business revenue composition includes 74.56% from iodides, 12.79% from specialty functional chemicals, 9.94% from trading, and 2.72% from other sources [2] - For the first half of 2025, Baoyuan Co. achieved an operating income of 747 million yuan, a year-on-year increase of 7.39%, while the net profit attributable to the parent company was 99.0429 million yuan, a year-on-year decrease of 19.09% [2] Group 3 - Baoyuan Co. has cumulatively distributed 88.408 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The company, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., is engaged in the research, production, and sales of fine chemicals, with a focus on iodine compounds and precious metal catalysts, showing a mixed financial performance in recent periods [2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in fine chemical products, including organic and inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes iodides (74.56%), specialty functional chemicals (12.79%), trading business (9.94%), and others (2.72%) [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 747 million yuan, representing a year-on-year growth of 7.39% [2]. - The net profit attributable to the parent company was 99.04 million yuan, which reflects a year-on-year decrease of 19.09% [2]. - As of September 19, the number of shareholders increased to 10,300, with an average of 3,233 circulating shares per person, a decrease of 1.00% from the previous period [2]. Group 3: Market Activity - On September 22, the company's stock rose by 1.41%, with a trading volume of 284 million yuan [1]. - The financing buy-in amount for the company on the same day was 23.83 million yuan, while the financing repayment was 36.46 million yuan, resulting in a net financing buy-in of -12.63 million yuan [1]. - The total margin trading balance for the company as of September 22 was 113 million yuan, accounting for 4.39% of the circulating market value [1].

Core Viewpoint - The stock of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. has shown significant price increases this year, with a year-to-date rise of 108.17% as of September 15, 2023, despite a recent decline in trading [1][2]. Group 1: Company Overview - Shandong Boyuan Pharmaceutical Chemical Co., Ltd. was established on August 6, 2008, and is located in Shouguang City, Shandong Province [2]. - The company specializes in the research, production, and sales of fine chemicals, including organic iodides, inorganic iodides, precious metal catalysts, luminescent materials, and hexamethyldisilazane [2]. - The revenue composition of the company includes 74.56% from iodides, 12.79% from specialty functional chemicals, 9.94% from trading, and 2.72% from other sources [2]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 747 million yuan, representing a year-on-year growth of 7.39%, while the net profit attributable to shareholders decreased by 19.09% to 99.04 million yuan [2]. - The company has distributed a total of 88.41 million yuan in dividends since its A-share listing [3]. Group 3: Stock Performance and Trading Activity - As of September 15, 2023, the stock price was 80.64 yuan per share, with a market capitalization of 10.777 billion yuan [1]. - The stock has experienced a trading volume of 1.17 billion yuan, with a turnover rate of 4.25% [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent net buy of 51.18 million yuan on September 9, 2023 [1].

Core Viewpoint - The company is expanding its business into hexamethyldisilazane products based on the common needs of its existing pharmaceutical clients and its advantages in resource utilization and technology [1] Group 1: Business Expansion - The company has identified a demand from its existing pharmaceutical clients for hexamethyldisilazane products, leading to its business expansion in this area [1] - The expansion into hexamethyldisilazane requires minimal additional investment and offers cost advantages in raw material acquisition [1] Group 2: Resource Utilization - The company has established a collaborative foundation in resource utilization, including operational qualifications, incineration facilities, shared equipment, production sites, practical experience, and a professional team [1] - The company is leveraging its strengths in waste recovery to extend its operations from organic solvent recovery to the recycling of siloxanes [1] Group 3: Market Positioning - Both iodides and hexamethyldisilazane are functional additives used in the pharmaceutical chemical process, sharing similar application scenarios and functional characteristics [1] - The company is strategically positioning itself in the market by utilizing its existing iodide products as a basis for the new hexamethyldisilazane product line, aligning with market demand and competitive landscape [1]